Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pediatrics
Published in: BMC Pediatrics 1/2022

Open Access 01-12-2022 | Cannabinoid | Research

Geotemporospatial and causal inference epidemiological analysis of US survey and overview of cannabis, cannabidiol and cannabinoid genotoxicity in relation to congenital anomalies 2001–2015

Authors: Albert Stuart Reece, Gary Kenneth Hulse

Published in: BMC Pediatrics | Issue 1/2022

Login to get access

Abstract

Background

Cannabinoids including cannabidiol have recognized genotoxic activities but their significance has not been studied broadly epidemiologically across the teratological spectrum. We examined these issues including contextual space-time relationships and formal causal inferential analysis in USA.

Methods

State congenital anomaly (CA) rate (CAR) data was taken from the annual reports of the National Birth Defects Prevention Network 2001–2005 to 2011–2015. Substance abuse rates were from the National Survey of Drug Use and Health a nationally representative longitudinal survey of the non-institutionalized US population with 74.1% response rate. Drugs examined were cigarettes, monthly and binge alcohol, monthly cannabis and analgesic and cocaine abuse. Early termination of pregnancy for abortion (ETOPFA) rates were taken from the published literature. Cannabinoid concentrations were from Drug Enforcement Agency. Ethnicity and income data were from the US Census Bureau. Inverse probability weighted (IPW) regressions and geotemporospatial regressions conducted for selected CAs.

Results

Data on 18,328,529 births from an aggregated population of 2,377,483,589 for mid-year analyses 2005–2013 comprehending 12,611 CARs for 62 CAs was assembled and ETOPFA-corrected (ETOPFACAR) where appropriate. E-Values for ETOPFACARs by substance trends were elevated for THC (40 CAs), cannabis (35 CAs), tobacco (11 CAs), cannabidiol (8 CAs), monthly alcohol (5 CAs) and binge alcohol (2 CAs) with minimum E-Values descending from 16.55, 1.55x107, 555.10, 7.53x1019, 9.30 and 32.98. Cardiovascular, gastrointestinal, chromosomal, limb reductions, urinary, face and body wall CAs particularly affected. Highest v. lowest substance use quintile CAR prevalence ratios 2.84 (95%C.I. 2.44, 3.31), 4.85 (4.08, 5.77) and 1.92 (1.63, 2.27) and attributable fraction in exposed 0.28 (0.27, 0.28), 0.57 (0.51, 0.62) and 0.47 (0.38, 0.55) for tobacco, cannabis and cannabidiol. Small intestinal stenosis or atresia and obstructive genitourinary defect were studied in detail in lagged IPW pseudo-randomized causal regressions and spatiotemporal models confirmed the causal role of cannabinoids. Spatiotemporal predictive modelling demonstrated strongly sigmoidal non-linear cannabidiol dose-response power-function relationships (P = 2.83x10−60 and 1.61x10−71 respectively).

Conclusions

Data implicate cannabinoids including cannabidiol in a diverse spectrum of heritable CAs. Sigmoidal non-linear dose-response relationships are of grave concern.
These transgenerational genotoxic, epigenotoxic, chromosomal-toxic putatively causal teratogenic effects strongly indicate tight restrictions on community cannabinoid penetration.
Appendix
Available only for authorised users
Literature
1.
Greenwich Biosciences. Epidiolex: Highlights of Prescribing Information. In: Food and Drug Administration, editor. Silver Springs: FDA; 2018. p. 1.
2.
3.
Brown SJ, Mensah FK, Ah Kit J, Stuart-Butler D, Glover K, Leane C, et al. Use of cannabis during pregnancy and birth outcomes in an Aboriginal birth cohort: a cross-sectional, population-based study. BMJ Open. 2016;6(2):e010286.PubMedPubMedCentralCrossRef
4.
Volkow ND, Compton WM, Wargo EM. The Risks of Marijuana Use During Pregnancy. Jama. 2017;317(2):129–30.PubMedCrossRef
5.
6.
Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, et al. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation. 2007;115(23):2995–3014.PubMedCrossRef
7.
Van Gelder MMHJ, Donders ART, Devine O, Roeleveld N, Reefhuis J. Using bayesian models to assess the effects of under-reporting of cannabis use on the association with birth defects, national birth defects prevention study, 1997-2005. Paediatr Perinat Epidemiol. 2014;28(5):424–33.PubMedPubMedCentralCrossRef
8.
Van Gelder MMHJ, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N. Maternal periconceptional illicit drug use and the risk of congenital malformations. Epidemiology. 2009;20(1):60–6.PubMedCrossRef
9.
10.
Brents L. Correlates and consequences of Prenatal Cannabis Exposure (PCE): Identifying and Characterizing Vulnerable Maternal Populations and Determining Outcomes in Exposed Offspring. In: Preedy VR, editor. Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis and Treatment. Volume 1, edn. London: Academic; 2017. p. 160–70.CrossRef
11.
Geber WF, Schramm LC. Effect of marihuana extract on fetal hamsters and rabbits. Toxicol Appl Pharmacol. 1969;14(2):276–82.PubMedCrossRef
12.
Graham JDP. Cannabis and Health. In: Graham JDP, editor. Cannabis and Health. Volume 1. 1st ed. London, New York, San Francisco: Academic; 1976. p. 271–320.
13.
Forrester MB, Merz RD. Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986-2002. J Toxicol Environ Health. 2007;70(1):7–18.CrossRef
14.
Jacobson CB, Berlin CM. Possible reproductive detriment in LSD users. Jama. 1972;222(11):1367–73.PubMedCrossRef
15.
Stenchever MA, Kunysz TJ, Allen MA. Chromosome breakage in users of marihuana. Am J Obstet Gynecol. 1974;118(1):106–13.PubMedCrossRef
16.
Reece AS, Hulse GK. Contemporary epidemiology of rising atrial septal defect trends across USA 1991-2016: a combined ecological geospatiotemporal and causal inferential study. BMC Pediatr. 2020;20(1):539.PubMedPubMedCentralCrossRef
17.
Reece AS, Hulse GK. Cannabis Consumption Patterns Explain the East-West Gradient in Canadian Neural Tube Defect Incidence: An Ecological Study. Glob Pediatr Health. 2019;6:2333794x19894798.PubMedPubMedCentral
18.
Reece AS, Hulse GK. Canadian Cannabis Consumption and Patterns of Congenital Anomalies: An Ecological Geospatial Analysis. J Addict Med. 2020;14(5):e195–210.PubMedPubMedCentralCrossRef
19.
Reece AS, Hulse GK. Broad Spectrum epidemiological contribution of cannabis and other substances to the teratological profile of northern New South Wales: geospatial and causal inference analysis. BMC Pharmacol Toxicol. 2020;21(1):75.PubMedPubMedCentralCrossRef
20.
Reece AS, Hulse GK. Cannabis Teratology Explains Current Patterns of Coloradan Congenital Defects: The Contribution of Increased Cannabinoid Exposure to Rising Teratological Trends. Clin Pediatr (Phila). 2019;58(10):1085–123.CrossRef
21.
Russo C, Ferk F, Mišík M, Ropek N, Nersesyan A, Mejri D, et al. Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells. Arch Toxicol. 2019;93(1):179–88.PubMedCrossRef
22.
Zimmerman AM, Zimmerman S, Raj AY. Effects of Cannabinoids on spermatogenesis in mice. In: Nahas GG, Sutin KM, Harvey DJ, Agurell S, editors. Marihuana and medicine. edn. Totowa: Humana Press; 1999. p. 347–58.CrossRef
23.
Mon MJ, Haas AE, Stein JL, Stein GS. Influence of psychoactive and nonpsychoactive cannabinoids on cell proliferation and macromolecular biosynthesis in human cells. Biochem Pharmacol. 1981;30(1):31–43.PubMedCrossRef
24.
Tahir SK, Zimmerman AM. Influence of marihuana on cellular structures and biochemical activities. Pharmacol Biochem Behav. 1991;40(3):617–23.PubMedCrossRef
25.
Mon MJ, Haas AE, Stein JL, Stein GS. Influence of psychoactive and nonpsychoactive cannabinoids on chromatin structure and function in human cells. Biochem Pharmacol. 1981;30(1):45–58.PubMedCrossRef
26.
Zimmerman AM, Raj AY. Influence of cannabinoids on somatic cells in vivo. Pharmacology. 1980;21(4):277–87.PubMedCrossRef
27.
Zimmerman AM, Stich H, San R. Nonmutagenic action of cannabinoids in vitro. Pharmacology. 1978;16(6):333–43.PubMedCrossRef
28.
29.
McClean DK, Zimmerman AM. Action of delta 9-tetrahydrocannabinol on cell division and macromolecular synthesis in division-synchronized protozoa. Pharmacology. 1976;14(4):307–21.PubMedCrossRef
30.
Parker SJ, Zuckerman BS, Zimmermann AM. The Effects of Maternal Marijuana Use During Pregnancy on Fetal Growth. In: Nahas GG, Sutin KM, Harvey DJ, Agurell S, editors. Marijuana in Medicine. Volume 1, edn. Totowa, New York: Humana Press; 1999. p. 461–8.
31.
Tahir SK, Trogadis JE, Stevens JK, Zimmerman AM. Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells. Biochem Cell Biol. 1992;70(10–11):1159–73.PubMedCrossRef
32.
Thomas J, Tilak S, Zimmerman S, Zimmerman AM. Action of delta 9-tetrahydrocannabinol on the pool of acid soluble nucleotides. Cytobios. 1984;40(158):71–85.PubMed
33.
Zimmerman AM, Zimmerman S. Cytogenetic Studies of Cannabinoid Effects. In: Braude MC, Zimmerman AM, editors. Genetic and Perinatal Effects of Abused Substances. Volume 1, edn. New York: Academic Press Inc.; Harcourt, Brace Jovanovich; 1987. p. 95–112.
34.
Zimmerman AM, Zimmerman S, Raj AY. Effects of Cannabinoids on Spermatogensis in Mice. In: Nahas GG, Sutin KM, Harvey DJ, Agurell S, editors. Marijuana and Medicine. Volume 1. 1st ed. Totowa, New York: Humana Press; 1999. p. 347–58.
35.
Takei Y, Yun J, Zheng S, Ollikainen N, Pierson N, White J, et al. Integrated spatial genomics reveals global architecture of single nuclei. Nature. 2021;590(7845):344–50.PubMedPubMedCentralCrossRef
36.
37.
DiNieri JA, Wang X, Szutorisz H, Spano SM, Kaur J, Casaccia P, et al. Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol Psychiatry. 2011;70(8):763–9.PubMedPubMedCentralCrossRef
38.
Szutorisz H, DiNieri JA, Sweet E, Egervari G, Michaelides M, Carter JM, et al. Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation. Neuropsychopharmacology. 2014;39(6):1315–23.PubMedPubMedCentralCrossRef
39.
Szutorisz H, Hurd YL. Epigenetic Effects of Cannabis Exposure. Biol Psychiatry. 2016;79(7):586–94.PubMedCrossRef
40.
Szutorisz H, Hurd YL. High times for cannabis: Epigenetic imprint and its legacy on brain and behavior. Neurosci Biobehav Rev. 2018;85:93–101.PubMedCrossRef
41.
Watson CT, Szutorisz H, Garg P, Martin Q, Landry JA, Sharp AJ, et al. Genome-Wide DNA Methylation Profiling Reveals Epigenetic Changes in the Rat Nucleus Accumbens Associated With Cross-Generational Effects of Adolescent THC Exposure. Neuropsychopharmacology. 2015;40(13):2993–3005.PubMedPubMedCentralCrossRef
42.
Fish EW, Murdaugh LB, Zhang C, Boschen KE, Boa-Amponsem O, Mendoza-Romero HN, et al. Cannabinoids Exacerbate Alcohol Teratogenesis by a CB1-Hedgehog Interaction. Sci Rep. 2019;9(1):16057.PubMedPubMedCentralCrossRef
43.
Bermejo-Sanchez E, Cuevas L, Amar E, Bakker MK, Bianca S, Bianchi F, et al. Amelia: a multi-center descriptive epidemiologic study in a large dataset from the International Clearinghouse for Birth Defects Surveillance and Research, and overview of the literature. Am J Med Genet C Semin Med Genet. 2011;157C(4):288–304.PubMedCrossRef
44.
Bermejo-Sanchez E, Cuevas L, Amar E, Bianca S, Bianchi F, Botto LD, et al. Phocomelia: a worldwide descriptive epidemiologic study in a large series of cases from the International Clearinghouse for Birth Defects Surveillance and Research, and overview of the literature. Am J Med Genet C Semin Med Genet. 2011;157C(4):305–20.PubMedCrossRef
45.
46.
47.
Willsher K. Baby arm defects prompt nationwide investigation in France. In: Guardian. London: The Guardian; 2018.
48.
Agence France-Presse in Paris. France to investigate cause of upper limb defects in babies. In: The Guardian. London: The Guardian; 2018.
49.
50.
Gant J. Scientists are baffled by spatter of babies born without hands or arms in France, as investigation fails to discover a cause. In: Daily Mail. vol. Sunday 14th July. London: Daily Mail; 2019.
51.
McBride WG. Thalidomide and Congenital Malformations. Lancet. 1962;2:1358–9.
52.
53.
Rehman W, Arfons LM, Lazarus HM. The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther Adv Hematol. 2011;2(5):291–308.PubMedPubMedCentralCrossRef
54.
Price PJ, Suk WA, Spahn GJ, Freeman AE. Transformation of Fischer rat embryo cells by the combined action of murine leukemia virus and (−)-trans- 9 -tetrahydrocannabinol. Proc Soc Exp Biol Med. 1972;140(2):454–6.PubMedCrossRef
55.
Busch FW, Seid DA, Wei ET. Mutagenic activity of marihuana smoke condensates. Cancer Lett. 1979;6(6):319–24.PubMedCrossRef
56.
Vela G, Martin S, Garcia-Gil L, Crespo JA, Ruiz-Gayo M, Fernandez-Ruiz JJ, et al. Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mu opioid receptors in adult offspring female rats. Brain Res. 1998;807(1–2):101–9.PubMedCrossRef
57.
Sarafian TA, Kouyoumjian S, Khoshaghideh F, Tashkin DP, Roth MD. Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. Am J Physiol. 2003;284(2):L298–306.
58.
Sarafian TA, Habib N, Oldham M, Seeram N, Lee RP, Lin L, et al. Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells in vivo. Am J Physiol. 2006;290(6):L1202–9.
59.
Morimoto S, Tanaka Y, Sasaki K, Tanaka H, Fukamizu T, Shoyama Y, et al. Identification and characterization of cannabinoids that induce cell death through mitochondrial permeability transition in Cannabis leaf cells. J Biol Chem. 2007;282(28):20739–51.PubMedCrossRef
60.
61.
Fisar Z, Singh N, Hroudova J. Cannabinoid-induced changes in respiration of brain mitochondria. Toxicol Lett. 2014;231(1):62–71.PubMedCrossRef
62.
Koller VJ, Auwarter V, Grummt T, Moosmann B, Misik M, Knasmuller S. Investigation of the in vitro toxicological properties of the synthetic cannabimimetic drug CP-47,497-C8. Toxicol Appl Pharmacol. 2014;277(2):164–71.PubMedCrossRef
63.
Koller VJ, Ferk F, Al-Serori H, Misik M, Nersesyan A, Auwarter V, et al. Genotoxic properties of representatives of alkylindazoles and aminoalkyl-indoles which are consumed as synthetic cannabinoids. Food Chem Toxicol. 2015;80:130–6.PubMedCrossRef
64.
Singh N, Hroudova J, Fisar Z. Cannabinoid-Induced Changes in the Activity of Electron Transport Chain Complexes of Brain Mitochondria. J Mol Neurosci. 2015;56(4):926–31.PubMedCrossRef
65.
Russo C, Ferk F, Misik M, Ropek N, Nersesyan A, Mejri D, et al. Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells. Arch Toxicol. 2019;93(1):179–88.
66.
Reece AS, Hulse GK. Effect of Cannabis Legalization on US Autism Incidence and Medium Term Projections. Clini Pediatr Open Access. 2019;4(2):1–17.
67.
VanderWeele TJ, Ding P, Mathur M. Technical Considerations in the Use of the E-Value. J Causal Inference. 2019;7(2):1–11.CrossRef
68.
VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268–74.PubMedCrossRef
69.
VanderWeele TJ, Mathur MB. Commentary: Developing best-practice guidelines for the reporting of E-values. Int J Epidemiol. 2020;49(5):1495–7.
70.
NBDPN. Major Birth Defects Data from Population-based Birth Defects Surveillance Programs in the United States, 2011–2015. In: Edited by Network NBDP, vol. NBDPN, CDC. NBDPN, Centers for Disease Control. Atlanta: National Birth Defects Prevention Network; 2018.
71.
72.
ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States. Biol Psychiatry. 2016;79(7):613–9.PubMedPubMedCentralCrossRef
73.
Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur Arch Psychiatry Clin Neurosci. 2019;269(1):5–15.PubMedCrossRef
74.
ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF 3rd. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci. 2000;45(1):24–30.PubMedCrossRef
75.
Bird TM, Hobbs CA, Cleves MA, Tilford JM, Robbins JM. National rates of birth defects among hospitalized newborns. Birth Defects Res A Clin Mol Teratol. 2006;76(11):762–9.PubMedCrossRef
76.
Natoli JL, Ackerman DL, McDermott S, Edwards JG. Prenatal diagnosis of Down syndrome: a systematic review of termination rates (1995-2011). Prenat Diagn. 2012;32(2):142–53.PubMedCrossRef
77.
Mansfield C, Hopfer S, Marteau TM. Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: a systematic literature review. European Concerted Action: DADA (Decision-making After the Diagnosis of a fetal Abnormality). Prenat Diagn. 1999;19(9):808–12.PubMedCrossRef
78.
Abeywardana S, Sullivan EA. Congenital Anomalies in Australia, 2002–2003. In: Edited by Australian Institute of Health and Welfare PSU, vol. Australian Institute of Health and Welfare. Sydney: Australian Institute of Health and Welfare; 2008.
79.
Brick DH, Allan LD. Outcome of prenatally diagnosed congenital heart disease: an update. Pediatr Cardiol. 2002;23(4):449–53.PubMedCrossRef
80.
Howell S, Endo T, MacLeod S, Cornes S. Congenital Anomalies in Queensland: 1 July 2007 to 30 June 2010. Statist Anal Rep #1. 2011;1(1):1–22.
81.
Siljee JE, Knegt AC, Knapen MF, Bekker MN, Visser GH, Schielen PC. Positive predictive values for detection of trisomies 21, 18 and 13 and termination of pregnancy rates after referral for advanced maternal age, first trimester combined test or ultrasound abnormalities in a national screening programme (2007-2009). Prenat Diagn. 2014;34(3):259–64.PubMedCrossRef
82.
Tararbit K, Bui TT, Lelong N, Thieulin AC, Goffinet F, Khoshnood B. Clinical and socioeconomic predictors of pregnancy termination for fetuses with congenital heart defects: a population-based evaluation. Prenat Diagn. 2013;33(2):179–86.PubMedCrossRef
83.
Women and Newborn Health Service, Department of Health, Government of Western Australia. Western Australian Register of Developmental Anomalies 1980–2014. In: Edited by Western Australia Health, vol. 1, vol. 28. Perth: Western Australia Health; 2015.
84.
85.
86.
Pearl J, Mackaenzie D. The Book of Why. The New Science of Cause and Effect, vol. 1. New York: Basic Books; 2019.
87.
Hölzel BN, Pfannkuche K, Allner B, Allner HT, Hescheler J, Derichsweiler D, et al. Following the adverse outcome pathway from micronucleus to cancer using H2B-eGFP transgenic healthy stem cells. Arch Toxicol. 2020;94(9):3265–80.PubMedPubMedCentralCrossRef
88.
Reece AS, Hulse GK. Epidemiological Associations of Various Substances and Multiple Cannabinoids with Autism in USA. Clin Pediatr Open Access. 2019;4(2):1–20.CrossRef
89.
Reece AS, Hulse GK. Epidemiological Overview of Multidimensional Chromosomal and Genome Toxicity of Cannabis Exposure in Congenital Anomalies and Cancer Development. Sci Rep. 2021;11(1):13892.PubMedPubMedCentralCrossRef
90.
Short TD, Stallings EB, Isenburg J, O'Leary LA, Yazdy MM, Bohm MK, et al. Gastroschisis Trends and Ecologic Link to Opioid Prescription Rates - United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2019;68(2):31–6.PubMedPubMedCentralCrossRef
91.
Reece AS, Wang W, Hulse GK. Pathways from epigenomics and glycobiology towards novel biomarkers of addiction and its radical cure. Med Hypotheses. 2018;116:10–21.PubMedCrossRef
92.
Carlson BM. Human Embryology and Developmental Biology, vol. 1. 6th ed. Philadelphia: Elsevier; 2019.
93.
Dyer LA, Kirby ML. Sonic hedgehog maintains proliferation in secondary heart field progenitors and is required for normal arterial pole formation. Dev Biol. 2009;330(2):305–17.PubMedPubMedCentralCrossRef
94.
Christ A, Marczenke M, Willnow TE. LRP2 controls sonic hedgehog-dependent differentiation of cardiac progenitor cells during outflow tract formation. Hum Mol Genet. 2020;29(19):3183–96.PubMedPubMedCentralCrossRef
95.
Yamagishi H, Maeda J, Hu T, McAnally J, Conway SJ, Kume T, et al. Tbx1 is regulated by tissue-specific forkhead proteins through a common Sonic hedgehog-responsive enhancer. Genes Dev. 2003;17(2):269–81.PubMedPubMedCentralCrossRef
96.
Hutson MR, Sackey FN, Lunney K, Kirby ML. Blocking hedgehog signaling after ablation of the dorsal neural tube allows regeneration of the cardiac neural crest and rescue of outflow tract septation. Dev Biol. 2009;335(2):367–73.PubMedPubMedCentralCrossRef
97.
Koefoed K, Skat-Rørdam J, Andersen P, Warzecha CB, Pye M, Andersen TA, et al. The E3 ubiquitin ligase SMURF1 regulates cell-fate specification and outflow tract septation during mammalian heart development. Sci Rep. 2018;8(1):9542.PubMedPubMedCentralCrossRef
98.
Maynard TM, Gopalakrishna D, Meechan DW, Paronett EM, Newbern JM, LaMantia A-S. 22q11 Gene dosage establishes an adaptive range for sonic hedgehog and retinoic acid signaling during early development. Hum Mol Genet. 2013;22(2):300–12.PubMedCrossRef
99.
100.
Sherif HMF. Heterogeneity in the Segmental Development of the Aortic Tree: Impact on Management of Genetically Triggered Aortic Aneurysms. Aorta (Stamford). 2014;2(5):186–95.CrossRef
101.
Kolesová H, Roelink H, Grim M. Sonic hedgehog is required for the assembly and remodeling of branchial arch blood vessels. Dev Dyn. 2008;237(7):1923–34.PubMedPubMedCentralCrossRef
102.
Kim JD, Kang H, Larrivée B, Lee MY, Mettlen M, Schmid SL, et al. Context-dependent proangiogenic function of bone morphogenetic protein signaling is mediated by disabled homolog 2. Dev Cell. 2012;23(2):441–8.PubMedPubMedCentralCrossRef
103.
104.
Geber WF, Schramm LC. Teratogenicity of marihuana extract as influenced by plant origin and seasonal variation. Arch Int Pharmacodyn Ther. 1969;177(1):224–30.PubMed
105.
Reece AS, Hulse GK. Gastroschisis and Autism-Dual Canaries in the Californian Coalmine. JAMA Surg. 2019;154(4):366–7.PubMedCrossRef
106.
Porath AJ, Fried PA. Effects of prenatal cigarette and marijuana exposure on drug use among offspring. Neurotoxicol Teratol. 2005;27(2):267–77.PubMedCrossRef
107.
Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana--a comparison with pre-drug performance. Neurotoxicol Teratol. 2005;27(2):231–9.PubMedCrossRef
108.
Fried P, Watkinson B, James D, Gray R. Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. CMAJ. 2002;166(7):887–91.PubMedPubMedCentral
109.
Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol. 2001;23(1):1–11.PubMedCrossRef
110.
Smith AM, Mioduszewski O, Hatchard T, Byron-Alhassan A, Fall C, Fried PA. Prenatal marijuana exposure impacts executive functioning into young adulthood: An fMRI study. Neurotoxicol Teratol. 2016;58:53–9.PubMedCrossRef
111.
Smith AM, Longo CA, Fried PA, Hogan MJ, Cameron I. Effects of marijuana on visuospatial working memory: an fMRI study in young adults. Psychopharmacology. 2010;210(3):429–38.PubMedCrossRef
112.
Smith AM, Fried PA, Hogan MJ, Cameron I. Effects of prenatal marijuana on visuospatial working memory: an fMRI study in young adults. Neurotoxicol Teratol. 2006;28(2):286–95.PubMedCrossRef
113.
114.
David AL, Holloway A, Thomasson L, Syngelaki A, Nicolaides K, Patel RR, et al. A case-control study of maternal periconceptual and pregnancy recreational drug use and fetal malformation using hair analysis. PLoS One. 2014;9(10):e111038.PubMedPubMedCentralCrossRef
115.
Draper ES, Rankin J, Tonks AM, Abrams KR, Field DJ, Clarke M, et al. Recreational drug use: a major risk factor for gastroschisis? Am J Epidemiol. 2008;167(4):485–91.PubMedCrossRef
116.
Skarsgard ED, Meaney C, Bassil K, Brindle M, Arbour L, Moineddin R, et al. Maternal risk factors for gastroschisis in Canada. Birth Defects Res A Clin Mol Teratol. 2015;103(2):111–8.PubMedCrossRef
117.
Torfs CP, Velie EM, Oechsli FW, Bateson TF, Curry CJ. A population-based study of gastroschisis: demographic, pregnancy, and lifestyle risk factors. Teratology. 1994;50(1):44–53.PubMedCrossRef
118.
Werler MM, Sheehan JE, Mitchell AA. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology. 2003;14(3):349–54.PubMedCrossRef
119.
Mon MJ, Jansing RL, Doggett S, Stein JL, Stein GS. Influence of delta9-tetrahydrocannabinol on cell proliferation and macromolecular biosynthesis in human cells. Biochem Pharmacol. 1978;27(13):1759–65.PubMedCrossRef
120.
Jakubovič A, McGeer PL, Fitzsimmons RC. Effects of Δ9-tetrahydrocannabinol and ethanol on body weight protein and nucleic acid synthesis in chick embryos. J Toxicol Environ Health. 1976;1(3):441–7.PubMedCrossRef
121.
Blevins RD, Regan JD. delta-9-Tetrahydrocannabinol: effect on macromolecular synthesis in human and other mammalian cells. Arch Toxicol. 1976;35(2):127–35.PubMedCrossRef
122.
Nahas GG, Morishima A, Desoize B. Effects of cannabinoids on macromolecular synthesis and replication of cultured lymphocytes. Fed Proc. 1977;36(5):1748–52.PubMed
123.
Pacher P, Steffens S, Hasko G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2018;15(3):151–66.PubMedCrossRef
124.
Molica F, Burger F, Thomas A, Staub C, Tailleux A, Staels B, et al. Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation. J Lipid Res. 2013;54(5):1360–8.PubMedPubMedCentralCrossRef
125.
Slavic S, Lauer D, Sommerfeld M, Kemnitz UR, Grzesiak A, Trappiel M, et al. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. J Mol Med (Berl). 2013;91(7):811–23.CrossRef
126.
Jouanjus E, Lapeyre-Mestre M, Micallef J, French Association of the Regional A, Dependence Monitoring Centres Working Group on Cannabis C. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc. 2014;3(2):e000638.PubMedPubMedCentralCrossRef
127.
128.
Folkerth RD, Habbe DM, Boyd TK, McMillan K, Gromer J, Sens MA, et al. Gastroschisis, destructive brain lesions, and placental infarction in the second trimester suggest a vascular pathogenesis. Pediatr Dev Pathol. 2013;16(5):391–6.PubMedPubMedCentralCrossRef
129.
Hoyme HE, Higginbottom MC, Jones KL. The vascular pathogenesis of gastroschisis: intrauterine interruption of the omphalomesenteric artery. J Pediatr. 1981;98(2):228–31.PubMedCrossRef
130.
Lubinsky M. A vascular and thrombotic model of gastroschisis. Am J Med Genet A. 2014;164A(4):915–7.PubMedCrossRef
131.
Pistor G, Marzheuser-Brands S, Weber G, Streich R. Intraoperative vascular assessment for estimation of risk in primary closure of omphalocele and gastroschisis. Pediatr Surg Int. 1996;11(2–3):86–90.PubMedCrossRef
132.
133.
Werler MM, Mitchell AA, Moore CA, Honein MA, National Birth Defects Prevention S. Is there epidemiologic evidence to support vascular disruption as a pathogenesis of gastroschisis? Am J Med Genet A. 2009;149A(7):1399–406.PubMedPubMedCentralCrossRef
134.
Ngan ESW, Kim KH, Hui CC. Sonic Hedgehog Signaling and VACTERL Association. Mol Syndromol. 2013;4(1–2):32–45.PubMedCrossRef
135.
Ryckebüsch L, Bertrand N, Mesbah K, Bajolle F, Niederreither K, Kelly RG, et al. Decreased levels of embryonic retinoic acid synthesis accelerate recovery from arterial growth delay in a mouse model of DiGeorge syndrome. Circ Res. 2010;106(4):686–94.PubMedPubMedCentralCrossRef
136.
Reece AS, Hulse GK. Rapid Response to Lane. Re: Cannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: a longitudinal study, 2016. BMJ Open. 2020;6:e011891–902.CrossRef
137.
Reece AS, Hulse GK. Response to Polocaro and Vettraino. Mo Med. 2020;117(6) In Press.
138.
Reece AS, Hulse GK. Chromothripsis and epigenomics complete causality criteria for cannabis- and addiction-connected carcinogenicity, congenital toxicity and heritable genotoxicity. Mutat Res. 2016;789:15–25.PubMedCrossRef
139.
Reece AS, Hulse GK. Impacts of Cannabinoid Epigenetics on Human Development: Reflections on Murphy et. al. 'Cannabinoid Exposure and Altered DNA Methylation in Rat and Human Sperm' Epigenetics 2018; 13: 1208-1221. Epigenetics. 2019:1–16.
140.
Murphy SK, Itchon-Ramos N, Visco Z, Huang Z, Grenier C, Schrott R, et al. Cannabinoid exposure and altered DNA methylation in rat and human sperm. Epigenetics. 2018;13(12):1208–21.
141.
Wilson RG Jr, Tahir SK, Mechoulam R, Zimmerman S, Zimmerman AM. Cannabinoid enantiomer action on the cytoarchitecture. Cell Biol Int. 1996;20(2):147–57.PubMedCrossRef
142.
Reece AS, Hulse GK. Impact of Lifetime Opioid Exposure on Arterial Stiffness and Vascular Age: Cross-sectional and Longitudinal Studies in Men and Women. BMJ Open. 2014;4(6):1–19.CrossRef
143.
Tyser RCV, Ibarra-Soria X, McDole K, Arcot Jayaram S, Godwin J, van den Brand TAH, et al. Characterization of a common progenitor pool of the epicardium and myocardium. Science. 2021;371(6533):eabb2986.PubMedCrossRef
144.
145.
Carlson BM. Human Embryology and Developmental Biology, vol. 1. 5th ed. Philadelphia: Elsevier; 2014.
146.
147.
Kizaki M, Hashimoto Y. New tubulin polymerization inhibitor derived from thalidomide: implications for anti-myeloma therapy. Curr Med Chem. 2008;15(8):754–65.PubMedCrossRef
148.
Iguchi T, Yachide-Noguchi T, Hashimoto Y, Nakazato S, Sagawa M, Ikeda Y, et al. Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide. Int J Mol Med. 2008;21(2):163–8.PubMed
149.
Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996;35(6):969–79.PubMedCrossRef
150.
Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci U S A. 2009;106(21):8573–8.PubMedPubMedCentralCrossRef
151.
Vargesson N. Thalidomide-induced limb defects: resolving a 50-year-old puzzle. Bioessays. 2009;31(12):1327–36.PubMedCrossRef
152.
153.
154.
155.
Linz W. Thalidomide and Congenital Abnormalities. Lancet. 1962;7223(i):271–2.
156.
157.
Aguado T, Romero E, Monory K, Palazuelos J, Sendtner M, Marsicano G, et al. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J Biol Chem. 2007;282(33):23892–8.PubMedCrossRef
158.
Williams EJ, Walsh FS, Doherty P. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J Cell Biol. 2003;160(4):481–6.PubMedPubMedCentralCrossRef
159.
Asimaki O, Leondaritis G, Lois G, Sakellaridis N, Mangoura D. Cannabinoid 1 receptor-dependent transactivation of fibroblast growth factor receptor 1 emanates from lipid rafts and amplifies extracellular signal-regulated kinase 1/2 activation in embryonic cortical neurons. J Neurochem. 2011;116(5):866–73.PubMedCrossRef
160.
Birerdinc A, Jarrar M, Stotish T, Randhawa M, Baranova A. Manipulating molecular switches in brown adipocytes and their precursors: a therapeutic potential. Prog Lipid Res. 2013;52(1):51–61.PubMedCrossRef
161.
Richard D, Picard F. Brown fat biology and thermogenesis. Front Biosci (Landmark Ed). 2011;16:1233–60.CrossRef
162.
Xu TR, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cell Signal. 2013;25(12):2413–23.PubMedCrossRef
163.
Fraher D, Ellis MK, Morrison S, McGee SL, Ward AC, Walder K, et al. Lipid Abundance in Zebrafish Embryos Is Regulated by Complementary Actions of the Endocannabinoid System and Retinoic Acid Pathway. Endocrinology. 2015;156(10):3596–609.PubMedCrossRef
164.
Kučukalić S, Ferić Bojić E, Babić R, Avdibegović E, Babić D, Agani F, et al. Genetic Susceptibility to Posttraumatic Stress Disorder: Analyses of the Oxytocin Receptor, Retinoic Acid Receptor-Related Orphan Receptor A and Cannabinoid Receptor 1 Genes. Psychiatr Danub. 2019;31(2):219–26.PubMedCrossRef
165.
Lee YS, Jeong WI. Retinoic acids and hepatic stellate cells in liver disease. J Gastroenterol Hepatol. 2012;27(Suppl 2):75–9.PubMedCrossRef
166.
Frampton G, Coufal M, Li H, Ramirez J, DeMorrow S. Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. Exp Cell Res. 2010;316(9):1465–78.PubMedPubMedCentralCrossRef
167.
Kim D, Lim S, Park M, Choi J, Kim J, Han H, et al. Ubiquitination-dependent CARM1 degradation facilitates Notch1-mediated podocyte apoptosis in diabetic nephropathy. Cell Signal. 2014;26(9):1774–82.PubMedCrossRef
168.
Lu T, Newton C, Perkins I, Friedman H, Klein TW. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J Pharmacol Exp Ther. 2006;319(1):269–76.PubMedCrossRef
169.
Newton CA, Chou PJ, Perkins I, Klein TW. CB(1) and CB(2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection. J NeuroImmune Pharmacol. 2009;4(1):92–102.PubMedCrossRef
170.
Niu F, Zhao S, Xu CY, Sha H, Bi GB, Chen L, et al. Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2. Oncol Lett. 2015;10(4):2415–21.PubMedPubMedCentralCrossRef
171.
Tanveer R, Gowran A, Noonan J, Keating SE, Bowie AG, Campbell VA. The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-beta and in the cortex of aged rats. J Biol Chem. 2012;287(41):34709–21.PubMedPubMedCentralCrossRef
172.
Xapelli S, Agasse F, Sarda-Arroyo L, Bernardino L, Santos T, Ribeiro FF, et al. Activation of type 1 cannabinoid receptor (CB1R) promotes neurogenesis in murine subventricular zone cell cultures. PLoS One. 2013;8(5):e63529.PubMedPubMedCentralCrossRef
173.
Proto MC, Fiore D, Piscopo C, Franceschelli S, Bizzarro V, Laezza C, et al. Inhibition of Wnt/beta-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer. Sci Rep. 2017;7(1):11678.PubMedPubMedCentralCrossRef
174.
Vallee A, Lecarpentier Y, Guillevin R, Vallee JN. Effects of cannabidiol interactions with Wnt/beta-catenin pathway and PPARgamma on oxidative stress and neuroinflammation in Alzheimer's disease. Acta Biochim Biophys Sin Shanghai. 2017;49(10):853–66.PubMedCrossRef
175.
Nallathambi R, Mazuz M, Namdar D, Shik M, Namintzer D, Vinayaka AC, et al. Identification of Synergistic Interaction Between Cannabis-Derived Compounds for Cytotoxic Activity in Colorectal Cancer Cell Lines and Colon Polyps That Induces Apoptosis-Related Cell Death and Distinct Gene Expression. Cannabis Cannabinoid Res. 2018;3(1):120–35.PubMedPubMedCentralCrossRef
176.
Petko J, Tranchina T, Patel G, Levenson R, Justice-Bitner S. Identifying novel members of the Wntless interactome through genetic and candidate gene approaches. Brain Res Bull. 2018;138:96–105.PubMedCrossRef
177.
Xian X, Tang L, Wu C, Huang L. miR-23b-3p and miR-130a-5p affect cell growth, migration and invasion by targeting CB1R via the Wnt/beta-catenin signaling pathway in gastric carcinoma. Onco Targets Ther. 2018;11:7503–12.PubMedPubMedCentralCrossRef
178.
McKenzie MG, Cobbs LV, Dummer PD, Petros TJ, Halford MM, Stacker SA, et al. Non-canonical Wnt Signaling through Ryk Regulates the Generation of Somatostatin- and Parvalbumin-Expressing Cortical Interneurons. Neuron. 2019;103(5):853–864 e854.PubMedPubMedCentralCrossRef
179.
Nalli Y, Dar MS, Bano N, Rasool JU, Sarkar AR, Banday J, et al. Analyzing the role of cannabinoids as modulators of Wnt/beta-catenin signaling pathway for their use in the management of neuropathic pain. Bioorg Med Chem Lett. 2019;29(9):1043–6.PubMedCrossRef
180.
Foldy C, Malenka RC, Sudhof TC. Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron. 2013;78(3):498–509.PubMedPubMedCentralCrossRef
181.
Radyushkin K, Hammerschmidt K, Boretius S, Varoqueaux F, El-Kordi A, Ronnenberg A, et al. Neuroligin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit. Genes Brain Behav. 2009;8(4):416–25.PubMedCrossRef
182.
183.
Alpar A, Tortoriello G, Calvigioni D, Niphakis MJ, Milenkovic I, Bakker J, et al. Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling. Nat Commun. 2014;5:4421.PubMedCrossRef
184.
Kangsamaksin T, Murtomaki A, Kofler NM, Cuervo H, Chaudhri RA, Tattersall IW, et al. NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth. Cancer Discov. 2015;5(2):182–97.PubMedCrossRef
185.
London NR, Li DY. Robo4-dependent Slit signaling stabilizes the vasculature during pathologic angiogenesis and cytokine storm. Curr Opin Hematol. 2011;18(3):186–90.PubMedPubMedCentralCrossRef
186.
Cardenas A, Villalba A, de Juan RC, Pico E, Kyrousi C, Tzika AC, et al. Evolution of Cortical Neurogenesis in Amniotes Controlled by Robo Signaling Levels. Cell. 2018;174(3):590–606 e521.PubMedPubMedCentralCrossRef
187.
Metadata
Title
Geotemporospatial and causal inference epidemiological analysis of US survey and overview of cannabis, cannabidiol and cannabinoid genotoxicity in relation to congenital anomalies 2001–2015
Authors
Albert Stuart Reece
Gary Kenneth Hulse
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Cannabinoid
Published in
BMC Pediatrics / Issue 1/2022
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-021-02996-3

Other articles of this Issue 1/2022

BMC Pediatrics 1/2022 Go to the issue

Research

Audit identified modifiable factors in Hospital Care of Newborns in low-middle income countries: a scoping review

Research

Primary vaginal endodermal sinus tumor in infants and children: experience from a tertiary center

Research

Growth and Nutritional Status of Phenylketonuric Children and Adolescents

Research

Association between cardiorrespiratory fitness and cognitive control: is somatic maturity an important mediator?

Research

Partial vaccination and associated factors among children aged 12–23 months in eastern Ethiopia

Research

Pre-hospital exposures to antibiotics among children presenting with fever in northern Uganda: a facility-based cross-sectional study